CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Arias, M.
Right arrow Articles by Weiskirchen, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Arias, M.
Right arrow Articles by Weiskirchen, R.
Cell Growth & Differentiation Vol. 13, 265-273, June 2002
© 2002 American Association for Cancer Research

Adenoviral Delivery of an Antisense RNA Complementary to the 3' Coding Sequence of Transforming Growth Factor-ß1 Inhibits Fibrogenic Activities of Hepatic Stellate Cells1

Monica Arias, Birgit Lahme, Eddy Van de Leur, Axel M. Gressner and Ralf Weiskirchen2

Institute of Clinical Chemistry and Pathobiochemistry, RWTH- University Hospital, D-52074 Aachen, Germany

Liver fibrosis occurs as a consequence of the transdifferentiationof hepatic stellate cells into myofibroblasts and is associated with an increased expression and activation of transforming growth factor (TGF)-ß1. This pluripotent, profibrogenic cytokine stimulates matrix synthesis and decreases matrix degradation, resulting in fibrosis. Thus, blockade of synthesis or sequestering of mature TGF-ß1 is a primary target for the development of antifibrotic approaches. The purpose of this study was to investigate whether the administration of adenoviruses constitutively expressing an antisense mRNA complementary to the 3' coding sequence of TGF-ß1 is able to suppress the synthesis of TGF-ß1 in culture-activated hepatic stellate cells. We demonstrate that the adenoviral vehicle directs high-level expression of the transgene and proved that the transduced antisense is biologically active by immunoprecipitation, Western blot, quantitative TGF-ß1 ELISA, and cell proliferation assays. Additionally, the biological function of the transgene was confirmed by analysis of differential activity of TGF-ß1-responsive genes using cell ELISA, Northern blotting, and by microarray technology, respectively. Furthermore, we examined the effects of that transgene on the expression of TGF-ß2, TGF-ß3, collagen type {alpha}1(I), latent transforming growth factor binding protein 1, types I and II TGF-ß receptors, and {alpha}-smooth muscle actin. Our results indicate that the administration of antisense mRNA offers a feasible approach to block autocrine TGF-ß1 signaling in hepatic stellate cells and may be useful and applicable in future to the treatment of fibrosis in chronic liver diseases.




This article has been cited by other articles:


Home page
Mol. Biol. CellHome page
M. Uemura, E. S. Swenson, M. D.A. Gaca, F. J. Giordano, M. Reiss, and R. G. Wells
Smad2 and Smad3 Play Different Roles in Rat Hepatic Stellate Cell Function and {alpha}-Smooth Muscle Actin Organization
Mol. Biol. Cell, September 1, 2005; 16(9): 4214 - 4224.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation
Copyright © 2002 by the American Association of Cancer Research.